0. DOCID:27511 SCORE: 0.00304741975270257
DOCNO: 9560835
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: genetics
AUTHOR: S E DePasquale SE
AUTHOR: A Giordano A
AUTHOR: A E Donnenfeld AE
AFFILIATION: Program in Woman's Oncology, Woman and Infants Hospital, Providence, RI 02905-2499, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Obstetrical & gynecological survey.
COUNTRY: UNITED STATES
TITLE: The genetics of ovarian cancer: molecular biology and clinical application.
PUBDATE: 19980401
Ovarian cancer is the fifth most common malignancy among American women and the fourth leading cause of cancer death. The rapid advances in molecular genetic analysis, presymptomatic detection, and treatment of ovarian cancer are staggering. In this review, both the genetic component and the molecular biology of ovarian cancer are discussed, as well as current recommendations for genetic counseling. It is important for the practicing obstetrician and gynecologist to become familiar with these concepts, for it is he or she who will likely serve as a primary resource of information for these patients.


1. DOCID:27907 SCORE: 0.00303936866054212
DOCNO: 10977932
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: pathology
QUALIFIER: pathology
QUALIFIER: pathology
AUTHOR: G I Nepomnyashchikh GI
AUTHOR: V A Levitskii VA
AUTHOR: L M Nepomnyashchikh LM
AUTHOR: S V Aidagulova SV
AUTHOR: L A Naumova LA
AUTHOR: I Y Belov IY
AFFILIATION: Laboratory of Ultrastructural Basis of Pathology, Institute of Regional Pathology and Pathomorphology, Siberian Division of Russian Academy of Medical Sciences, Novosibirsk.
PUBTYPE: Journal Article
JOURNALTITLE: Bulletin of experimental biology and medicine.
COUNTRY: United States
TITLE: Instability of bronchial epithelium in chronic pulmonary diseases.
PUBDATE: 20000401
Pathomorphological examination of large bronchi in patients with occupational diseases, lung cancer, and in subjects exposed to radiation revealed structural and functional heterogeneity of the epithelium: the presence of focal atrophy, metaplasia, hyper- and dysplasia in the same biopsy specimen. This phenomenon was termed as instability of the epithelium. Thickness of the epithelium greatly varied, especially, in neoplastic processes. Atrophy and epithelial instability phenomenon are interpreted as morphological markers of ecological and oncological risk.


2. DOCID:27971 SCORE: 0.00303936812577775
DOCNO: 10854151
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Genetic Vectors
QUALIFIER: genetics
QUALIFIER: therapy
QUALIFIER: therapy
QUALIFIER: methods
AUTHOR: L C Pagliaro LC
AFFILIATION: Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA. lpagliar@mdanderson.org
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: World journal of urology.
COUNTRY: GERMANY
TITLE: Gene therapy for bladder cancer.
PUBDATE: 20000401
Tumor-suppressor genes can be transferred into tumor cells in vivo using a replication-defective adenoviral vector. P53 mutations are frequent in bladder cancer, and adenovirus-mediated p53 gene transfer is growth-inhibitory to bladder cancer cells in vitro. The vector Ad5CMV-P53, which contains human wild-type p53, is being administered intravesically to patients with bladder cancer in a phase I clinical trial. The results of this study will provide the basis for phase II and phase III trials in which gene therapy will be integrated with existing therapies for improved local control and opportunities for bladder preservation.


3. DOCID:27968 SCORE: 0.00303936766963476
DOCNO: 11561985
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
AUTHOR: R Dreicer R
AFFILIATION: Department of Hematology, The Urologic Institute, Cleveland Clinic Foundation, OH 44195, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Seminars in urologic oncology.
COUNTRY: United States
TITLE: Neoadjuvant chemotherapy in the management of muscle-invasive bladder cancer.
PUBDATE: 20010801
Muscle-invasive bladder cancer is typically an aggressive solid tumor with the propensity for early systemic dissemination. Although radical cystectomy remains the gold standard intervention, the high rate of systemic failure has prompted investigators to evaluate various strategies to attempt to improve survival, including the early administration of systemic chemotherapy. These efforts have provided mixed results with two recently completed trials providing conflicting results. Other strategies include attempts to both preserve the bladder using combinations of limited surgical resection, systemic chemotherapy, and radiotherapy. This review focuses on the potential of neoadjuvantly administered therapies to impact the management of muscle-invasive bladder cancer.


4. DOCID:26965 SCORE: 0.00280172185847864
DOCNO: 10048254
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Patient Selection
QUALIFIER: therapeutic use
QUALIFIER: complications
QUALIFIER: drug therapy
AUTHOR: C Hassed C
AFFILIATION: Monash University Department of Community Medicine.
PUBTYPE: Journal Article
JOURNALTITLE: Australian family physician.
COUNTRY: AUSTRALIA
TITLE: Choosing an opioid analgesic for cancer patients.
PUBDATE: 19990201
The following is a supplement to the article on the management of cancer pain which appeared in the January edition of AFP. It will provide some more detailed information on the choice and prescribing of opioid analgesics other than morphine for cancer patients. One should, of course, bear in mind many of the comments made in the original article regarding the holistic assessment of patients and their pain, the use of adjuvant therapies and alternatives. For more complete information regarding their use and pharmacokinetics one may need to consult product information, MIMS or one of the excellent short books designed for GPs.


5. DOCID:31048 SCORE: 0.00265792404514176
DOCNO: 15993065
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: chemical synthesis
QUALIFIER: chemistry
QUALIFIER: chemical synthesis
AUTHOR: Timothy A Blizzard TA
AUTHOR: Frank DiNinno F
AUTHOR: Helen Y Chen HY
AUTHOR: Seongkon Kim S
AUTHOR: Jane Y Wu JY
AUTHOR: Wanda Chan W
AUTHOR: Elizabeth T Birzin ET
AUTHOR: Yi Tien Yang YT
AUTHOR: Lee-Yuh Pai LY
AUTHOR: Edward C Hayes EC
AUTHOR: Carolyn A DaSilva CA
AUTHOR: Susan P Rohrer SP
AUTHOR: James M Schaeffer JM
AUTHOR: Milton L Hammond ML
AFFILIATION: Merck Research Laboratories, RY800-B116, P.O. Box 2000, Rahway, NJ 07065, USA. tim.blizzard@merck.com
PUBTYPE: Journal Article
JOURNALTITLE: Bioorganic & medicinal chemistry letters.
COUNTRY: England
TITLE: Estrogen receptor ligands. Part 13: Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain.
PUBDATE: 20050901
An optimized side chain for dihydrobenzoxathiin SERAMs was discovered and attached to four dihydrobenzoxathiin platforms. The novel SERAMs show exceptional estrogen antagonist activity in uterine tissue and an MCF-7 breast cancer cell assay.


6. DOCID:31137 SCORE: 0.00265792312014053
DOCNO: 16143160
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: analogs & derivatives
QUALIFIER: drug therapy
AUTHOR: Howard A Burris HA
AFFILIATION: The Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville, USA. hburris@tnonc.com
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Seminars in oncology.
COUNTRY: United States
TITLE: Recent updates on the role of chemotherapy in pancreatic cancer.
PUBDATE: 20050801
Single-agent gemcitabine remains the standard treatment for advanced pancreatic cancer. Recent phase III trials have failed to show improvements in survival using gemcitabine in combination with other chemotherapeutic agents, although the gemcitabine/oxaliplatin combination has shown some promise. The combination of gemcitabine with erlotinib was associated with a significant prolongation of survival. Promising results in a phase II trial of gemcitabine in combination with bevacizumab have led to a randomized comparative trial of the combination. Potential combinations with other biologic agents are being investigated.


7. DOCID:29408 SCORE: 0.00263601839814681
DOCNO: 16281265
OWNER: NLM
STATUS: In-Process
AUTHOR: Philippe Vignal P
PUBTYPE: Journal Article
JOURNALTITLE: Journal of clinical ultrasound : JCU.
COUNTRY: United States
TITLE: Sonographic appearance of a carcinoma developed in ectopic axillary breast tissue.
PUBDATE: 20051201
Primary breast cancer of ectopic axillary breast tissue is almost never diagnosed preoperatively. When not accompanied by nipple-areolar complex, the mass is often believed to be a lipoma, an enlarged lymph node, or a skin lesion such as a sebaceous cyst or hydradenitis suppurativa. When an axillary mass is found, a percutaneous needle biopsy is mandatory to rule out the diagnosis of cancer in ectopic breast tissue. We describe the sonographic findings of a case of ductal carcinoma in axillary ectopic breast tissue.


8. DOCID:31262 SCORE: 0.00250075944347158
DOCNO: 15830143
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Quality of Life
DESCRIPTOR: Questionnaires
QUALIFIER: complications
QUALIFIER: pathology
AUTHOR: Kathleen J Yost KJ
AUTHOR: Susan E Yount SE
AUTHOR: David T Eton DT
AUTHOR: Cheryl Silberman C
AUTHOR: Anne Broughton-Heyes A
AUTHOR: David Cella D
AFFILIATION: Center on Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare Research Institute, 1001 University Place, Suite 100, Evanston, IL 60201, USA. kyost@enh.org
PUBTYPE: Journal Article
PUBTYPE: Validation Studies
JOURNALTITLE: Breast cancer research and treatment.
COUNTRY: Netherlands
TITLE: Validation of the Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI).
PUBDATE: 20050401
We assessed the reliability, validity, and responsiveness to change of the 6-item Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI) in a sample of 615 metastatic breast cancer patients. The FBSI is a brief, clinically relevant, and psychometrically sound instrument that can be used to measure symptoms in patients with breast cancer.


9. DOCID:27318 SCORE: 0.00249955146376783
DOCNO: 9492823
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Neoplasm Circulating Cells
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
QUALIFIER: secondary
QUALIFIER: drug therapy
QUALIFIER: pathology
AUTHOR: K Tsushima K
AUTHOR: Y Sakata Y
AFFILIATION: First Dept. of Internal Medicine, Hirosaki University, School of Medicine, Japan.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Gan to kagaku ryoho. Cancer & chemotherapy.
COUNTRY: JAPAN
TITLE: [Treatment of recurrent gastric cancer]
PUBDATE: 19980201
The recurrence rate of resected gastric cancer with curative intent was around 20%. When early gastric cancer was excluded, the rate was around 30%. Peritoneal dissemination accounted for half the recurrences, and was followed by hematogeneous metastasis, including hepatic metastasis. Chemotherapy was the main treatment modality because the possibility of curative resection was very low. Systemic chemotherapies based on biochemical modulation, particularly CDDP/5-FU therapy, have been routinely performed. For localized diseases, loco-regional therapies like drug administration via hepatic artery and intraperitoneal administration have been also applied.


10. DOCID:27286 SCORE: 0.00249955111377206
DOCNO: 10471049
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Heterozygote Detection
DESCRIPTOR: Mutation
DESCRIPTOR: Protein-Serine-Threonine Kinases
QUALIFIER: genetics
QUALIFIER: genetics
AUTHOR: D G Bebb DG
AUTHOR: Z Yu Z
AUTHOR: J Chen J
AUTHOR: M Telatar M
AUTHOR: K Gelmon K
AUTHOR: N Phillips N
AUTHOR: R A Gatti RA
AUTHOR: B W Glickman BW
AFFILIATION: Centre for Environmental Health, Department of Biology, University of Victoria, Canada.
PUBTYPE: Journal Article
JOURNALTITLE: British journal of cancer.
COUNTRY: SCOTLAND
TITLE: Absence of mutations in the ATM gene in forty-seven cases of sporadic breast cancer.
PUBDATE: 19990801
Epidemiological evidence points to an increased risk of breast cancer in ataxia telangiectasia (AT) heterozygote women. Previous attempts to screen early onset or familial breast cancer patients failed to confirm an association. The issue of AT and late onset sporadic breast cancer remained unresolved. We screened 47 women who developed later onset, sporadic breast cancer for ataxia telangiectasia mutated (ATM) mutations. No mutations were found.


11. DOCID:26201 SCORE: 0.00238199802849348
DOCNO: 11446083
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: radiotherapy
QUALIFIER: etiology
QUALIFIER: etiology
QUALIFIER: radiotherapy
QUALIFIER: etiology
AUTHOR: L Kochbati L
AUTHOR: H Boussen H
AUTHOR: S Gritli S
AUTHOR: M Besbes M
AUTHOR: F Benna F
AUTHOR: A Saadi A
AUTHOR: A el May A
AUTHOR: F Ben Ayed F
AUTHOR: A Ladgham A
AUTHOR: M Maalej M
AFFILIATION: Service de radiothérapie, institut Salah-Azaïz Bab Saadoun, Tunis, Tunisie.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Cancer radiothérapie : journal de la Société française de radiothérapie oncologique.
COUNTRY: France
TITLE: [Secondary mandibular fibrosarcoma after chemoradiotherapy for undifferentiated nasopharyngeal carcinoma. Report of a case and review of the literature]
PUBDATE: 20010601
Secondary tumours to radio- and/or chemotherapy have rarely been reported after treatment for head and neck cancers. We report a case of mandibular fibrosarcoma observed 7 years after chemoradiotherapy for undifferentiated nasopharyngeal carcinoma in a patient treated when 20 years old.


12. DOCID:24595 SCORE: 0.00236900995659728
DOCNO: 11299868
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: complications
QUALIFIER: diagnosis
QUALIFIER: complications
QUALIFIER: diagnosis
AUTHOR: S Saortay S
AUTHOR: L Major L
AUTHOR: E Svastics E
AFFILIATION: Budai MAV Kórház, Sebészeti-Mellkassebészeti Osztály.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Magyar sebészet.
COUNTRY: Hungary
TITLE: [Paraesophageal hiatal hernia complicated with stomach cancer]
PUBDATE: 20010201
The authors present the history of a 79 years old female patient who had to be operated on with paraesophageal hiatal hernia causing cahexia, hematemesis, dysphagia and pain. They found an upside down stomach with cancer inside. They emphasize that endoscopy is very important in the diagnostic process and that cancer can develop even if the stomach is located in the chest.


13. DOCID:27168 SCORE: 0.00231485497597688
DOCNO: 10769574
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Magnetic Resonance Imaging
QUALIFIER: pathology
AUTHOR: D Brisbois D
AUTHOR: J F Biquet JF
AUTHOR: D Hock D
AUTHOR: P Magotteaux P
AFFILIATION: Service d'Imagerie médicale, Les Cliniques Saint-Joseph, Liège.
PUBTYPE: Journal Article
JOURNALTITLE: Revue médicale de Liège.
COUNTRY: BELGIUM
TITLE: [State of the art of pancreatic cancer imaging]
PUBDATE: 20000201
Ultrasonography and CT-scanner remain the first choice nowadays concerning detection and preoperative work-up of pancreatic cancer. MRI offers interesting options for the detection of liver metastases, and high quality of ductal and vascular examination. Actually, while we await a larger diffusion of MR systems and radiological expertise this technique is preferentially indicated as a third-step procedure when ultrasonography and CT-scanner are normal despite a real suspicion. Otherwise, MRI permits with a single non-invasive examination a complete work-up useful to prepare palliative therapy in case of unresectable tumor.


14. DOCID:29831 SCORE: 0.0022463991025495
DOCNO: 11966724
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: epidemiology
AUTHOR: Thomas L Diepgen TL
AUTHOR: V Mahler V
AFFILIATION: Department of Clinical Social Medicine and Dermato-Epidemiology, University Hospital Heidelberg, Bergheimer Str. 58, 69115 Heidelberg, Germany. thomas.diepgen@med.uni-heidelberg.de
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: The British journal of dermatology.
COUNTRY: England
TITLE: The epidemiology of skin cancer.
PUBDATE: 20020401
Melanoma and non-melanoma (basal and squamous cell carcinoma) skin cancer (NMSC) are now the most common types of cancer in the white populations and the incidence of skin cancer has reached epidemic proportions. According to recent population-based studies from Australia the incidence rate is over 2% for basal cell carcinoma in males and 1% for squamous cell carcinoma, and there are over 50 new cases of melanoma per 100 000.